The UK's second-biggest drug maker is licensing seven established anesthetic medicines to Aspen Global Incorporate (AGI),those beingDiprivan for general anesthesia, topical anesthetic EMLA and five local anesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest; see table below for full details).
Aspen Acquires AstraZeneca Anesthetics Portfolio Ex-US
Continuing its divesture of non-core assets, AstraZeneca PLC has licensed rights to its global anesthetics portfolio outside the US to South Africa's Aspen Global Incorporated
More from Business
• By
Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.
• By
Public Company Edition: Biohaven secured $250m up front from Oberland Capital to support its future US troriluzole launch after pulling its EU filing. Also, Procaps arranged $130m in private equity and Rezolute grossed $96.9m in a rare follow-on offering, among other financings.
• By
On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.